Psychotropic drug use in children
PI: Alan R. Ellis, PhD, MSW
Research Assistants: Casey Smith, MSW; Hazel Bright, BA; Mary Byrd Pettenati, BA; Lauren Moore, BS
Librarians: Kristine Alpi, MLS, MPH, AHIP; Jennifer Garrett, MLIS
Prescription drug expenses drive U.S. mental health spending,1 and psychotropic medication use–even in preschool-aged children– has increased dramatically over the past 20 years.1-7 Although psychotropic medication represents standard treatment for many mental disorders, its increasing use among children has raised concern. Psychotropic use in preschool children,4,8 which often has the purpose of treating attention deficit/hyperactivity disorder (ADHD) or associated symptoms,8-11 is especially concerning. Psychiatric diagnosis of children is notoriously difficult.12 Also, although ADHD screening instruments are available for children as young as 3 years,13,14 some children receive stimulants without an ADHD diagnosis.11 Even among those with such a diagnosis, treatment varies widely.9,10 Further, although preschool children may be vulnerable to side effects, we lack safety and effectiveness information for this group, particularly with regard to antipsychotics and mood stabilizers.8,15 Correspondingly, much psychotropic medication use among children under 6 is off-label. Other concerns include polypharmacy,12,16 medication use in the absence of psychosocial treatment or well-child care,9,12 and the fact that most psychotropic medications used by preschoolers are prescribed by primary care physicians,8,11 who may not always be as well-prepared for this responsibility as psychiatrists.12
A preliminary study of psychotropic medication use among North Carolina preschoolers, based on aggregated Medicaid data, found rates high enough to warrant continued attention.17 Findings showed a tenfold difference in rates between areas with the highest and lowest use, and suggested that psychotropic use may be higher in areas with fewer alternatives (e.g., fewer psychiatric and primary care providers). Combined with the above information, this apparent disparity highlights a pressing need to understand psychotropic use in children, how it varies, and what explains its variation.
We are currently conducting a rigorous, but brief, systematic review (a “scoping review”) to describe the current state of knowledge about psychotropic drug use in U.S. children. We are examining (a) rates of utilization of psychotropic drugs in U.S. children and (b) factors predicting utilization. We aim to complete this review in May 2016. Our findings will support further investigations of the predictors of use and the perceptions of multiple stakeholders about psychotropic medication use in children.
1. Frank RG, Goldman HH, McGuire TG. Trends in mental health cost growth: An expanded role for management? Health Aff (Millwood). 2009;28(3):649-659. doi:10.1377/hlthaff.28.3.649 [doi].
2. Substance Abuse and Mental Health Services Administration. National expenditures for mental health services and substance abuse treatment, 1986-2005. DHHS publication no. (SMA) 10-4612. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2010.
3. Olfson M, Blanco C, Wang S, Laje G, Correll CU. National trends in the mental health care of children, adolescents, and adults by office-based physicians. JAMA psychiatry. 2014;71(1):81- 90.
4. Zito JM, Safer DJ, Gardner JF, Boles M, Lynch F. Trends in the prescribing of psychotropic medications to preschoolers. JAMA. 2000;283(8):1025-1030.
5. Zito JM, Safer DJ, Gardner JF, et al. Psychotropic practice patterns for youth: A 10-year perspective. Arch Pediatr Adolesc Med. 2003;157(1):17-25.
6. Zito JM, Safer DJ, Zuckerman IH, Gardner JF, Soeken K. Effect of medicaid eligibility category on racial disparities in the use of psychotropic medications among youths. Psychiatric Services. 2005;56(2):157-163.
7. Martin A, Van Hoof T, Stubbe D, Sherwin T, Scahill L. Multiple psychotropic pharmacotherapy among child and adolescent enrollees in connecticut medicaid managed care. Psychiatric Services. 2014.
8. Minde K. The use of psychotropic medication in preschoolers: Some recent developments. The Canadian Journal of Psychiatry/La Revue canadienne de psychiatrie. 1998.
9. Rappley MD, Mullan PB, Alvarez FJ, Eneli IU, Wang J, Gardiner JC. Diagnosis of attention- deficit/hyperactivity disorder and use of psychotropic medication in very young children. Arch Pediatr Adolesc Med. 1999;153(10):1039-1045.
10. Rappley MD, Eneli IU, Mullan PB, et al. Patterns of psychotropic medication use in very young children with attention-deficit hyperactivity disorder. Journal of Developmental & Behavioral Pediatrics. 2002;23(1):23-30.
11. DeBar LL, Lynch F, Powell J, Gale J. Use of psychotropic agents in preschool children: Associated symptoms, diagnoses, and health care services in a health maintenance organization. Arch Pediatr Adolesc Med. 2003;157(2):150-157.
12. Barbaresi WJ. Use of psychotropic medications in young, preschool children: Primum non nocere. Arch Pediatr Adolesc Med. 2003;157(2):121-123.
13. Conners CK, Sitarenios G, Parker JD, Epstein JN. The revised conners’ parent rating scale (CPRS-R): Factor structure, reliability, and criterion validity. J Abnorm Child Psychol. 1998;26(4):257-268.
14. Conners CK, Sitarenios G, Parker JD, Epstein JN. Revision and restandardization of the conners teacher rating scale (CTRS-R): Factor structure, reliability, and criterion validity. J Abnorm Child Psychol. 1998;26(4):279-291.
15. Greenhill LL. The use of psychotropic medication in preschoolers: Indications, safety, and efficacy. Canadian journal of psychiatry. 1998;43(6):576-581.
16. Safer DJ, Zito JM, dosReis S. Concomitant psychotropic medication for youths. Am J Psychiatry. 2003;160(3):438-449.
17. Ellis AR. The administration of psychotropic medication to children ages 0–4 in north carolina. NC Med J. 2010;71(1).